Safety of Lienal Polypeptide Injection Combined with Chemotherapy in Treating Patients with Advanced Cancer |
Huang, Xin-En
(Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Wang, Lin (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Ji, Zhu-Qing (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Liu, Meng-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Qian, Ting (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) Li, Li (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) |
1 | Alisa A, Ives A, Pathan AA, et al (2005). Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res, 11, 6686-94. DOI |
2 | Alving CR, Peachman KK, Rao M, et al (2012). Adjuvants for human vaccines. Curr Opin Immunol, 24, 310-5. DOI |
3 | Arihara F, Mizukoshi E, Kitahara M, et al (2013). Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother, 62, 1421-30. DOI |
4 | Arruebo M, Fernandez-Pacheco R, Ibarra MR, et al (2007). Magnetic nanoparticles for drug delivery. Nano Today, 2, 22-32. |
5 | Belardelli F, Ferrantini M, Proietti E, et al (2002). Interferonalpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 13, 119-34. DOI |
6 | Bode C, Zhao G, Steinhagen F, et al (2011). CpG DNA as a vaccine adjuvant. Expert Rev Vaccines, 10, 499-511. DOI |
7 | Brannon-Peppas L, Blanchette JO (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 56, 1649-59. DOI |
8 | Chen KJ, Lin SZ, Zhou L, et al (2011). Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One, 6, e24671. DOI |
9 | Chen W, Zheng R, Zeng H, et al (2014). Trend analysis of the changes of male/female, urban/rural incidences and average age of cancer patients in China 1989-2008. Chin J Oncol, 36, 796-800. |
10 | Chen Z, Shen S, Peng B, et al (2009). Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model. Int J Hyperthermia, 25, 374-82. DOI |
11 | Cheng M, Chen Y, Xiao W, et al (2013). NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol, 10, 230-52. DOI |
12 | Cheng Y, Zhang G, Li G (2013). Targeting MAPK pathway in melanoma therapy. Cancer Metastasis Rev, 32, 567-84. DOI |
13 | Crispe IN, Giannandrea M, Klein I, et al (2006). Cellular and molecular mechanisms of liver tolerance. Immunol Rev, 213, 101-18. DOI |
14 | Ferlay J, Shin H, Bray F, et al (). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide; IARC Cancer Base No. 10; International Agency for Research on Cancer: Lyon, France, 2010; Volume 2010, p. 29. |
15 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
16 | Gao Q, Qiu SJ, Fan J, et al (2007). Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol, 25, 2586-2593. DOI |
17 | Hoechst B, Voigtlaender T, Ormandy L, et al (2009). Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 50, 799-807. DOI |
18 | Ilkovitch D, Lopez DM (2009). The liver is a site for tumorinduced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res, 69, 5514-21. DOI |
19 | Kalyanaraman B, Joseph J, Kalivendi S, et al (2002). Doxorubicininduced apoptosis: implications in cardiotoxicity. Mol Cell Biochem, 234-235, 119-124. DOI |
20 | Komorizono Y, Kohara K, Oketani M, et al (2003). Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Dig Dis Sci, 48, 877-81. DOI |
21 | Lin SM, Lin CJ, Hsu CW, et al (2004). Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer, 100, 376-82. DOI |
22 | Liu L (2014). The global significance of China's cancer burden and control effort. Ann Transl Med, 2014, 2. |
23 | National Bureau of Statistics of China (2011). China Population and Employment Statistics Yearbook, China Statistics Press: Beijing, China, 2012. |
24 | Ozols RF, Herbst RS, Colson YL, et al (2006). Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American society of clinical oncology. Jpn J Clin Oncol, 25, 146-62. DOI |
25 | Naumov GN, Townson JL, MacDonald IC, et al (2003). Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat, 82, 199-206. DOI |
26 | Obi S, Yoshida H, Toune R, et al (2006). Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer, 106, 1990-7. DOI |
27 | Ormandy LA, Hillemann T, Wedemeyer H, et al (2005). Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 65, 2457-64. DOI |
28 | Patt YZ, Hassan MM, Lozano RD, et al (2003). Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol, 21, 421-7. DOI |
29 | Peng XH, Qian X, Mao H, et al (2008). Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine, 3, 311-21. |
30 | Rosenberg SA, Yang JC, Restifo NP, et al (2004). Cancer immunotherapy: moving beyond current vaccines. Nat Med, 10, 909-15. DOI |
31 | Rosenberg SA (2001). Progress in human tumour immunology and immuno-therapy. Nature, 411, 380-4. DOI |
32 | Rosenberg SA, Yang JC, White DE, et al (1998). Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg, 228, 307-19. DOI |
33 | Shurin MR, Naiditch H, Gutkin DW, et al (2012). ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. Curr Med Chem, 19, 1792-803. DOI |
34 | Rougier P, Mitry E, Barbare JC, et al (2007). Hepatocellular carcinoma (HCC): an update. Semin Oncol, 34, S12-20. DOI |
35 | Schuster M, Nechansky A, Kircheis R (2006) . Cancer immunotherapy. Biotechnol J, 1, 138-47. DOI |
36 | Serda RE (2013) . Particle platforms for cancer immunotherapy. Int J Nanomedicine, 8, 1683-96. |
37 | Singh RK, Gutman M, Bucana CD, et al (1995). Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA, 92, 4562-6. DOI |
38 | Sun HC, Tang ZY, Wang L, et al (2006). Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol, 132, 458-65. DOI |
39 | Talmadge JE (1998). Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev, 33, 241-52. DOI |
40 | Vadrot N, Legrand A, Nello E, et al (2006). Inducible nitric oxide synthase (iNOS) activity could be responsible for resistance or sensitivity to IFN-gamma-induced apoptosis in several human hepatoma cell lines. J Interferon Cytokine Res, 26, 901-13. DOI |
41 | WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available online: http://globocan.iarc.fr (accessed on 17 May 2015). |